Antibody Engineering & Therapeutics Asia

October 21–23, 2024
Westin Miyako Kyoto,
Kyoto, Japan

Asia's Leading Conference To Accelerate Antibody/Protein Therapeutics, ADCs, Bispecifics & Immuno-Oncology

Keynote Speaker Provides Valuable Insights on Antibody Design

Design of Therapeutic Antibody with Engineered Binding Specificity

Tomoyuki Igawa, Ph.D., Associate President, Head of Translational Research Division, Chugai Pharmaceutical Co., Ltd., Japan

Two Optional Pre-Conference Workshops to Help You Accelerate Your Antibody and ADC Programs

Workshop A: Introduction to Antibody Engineering
Workshop B: Introduction to ADC Design and Development

Register Today to Learn from Case Studies and New Data

- Bispecific and Multispecific Antibodies
- Clinical Antibody and ADC Programs and Lessons Learned
- AI-Guided Antibody Discovery & Engineering
- Antibody Engineering, Discovery and Selection
- Alternative Non-Antibody Scaffolds

Media Partners:

Antibody Society of Japan

Antibody Society of Korea

Japan Bioindustry Association

Book by August 2 to save up to $300 | www.AntibodyEngAsia.com

New Technologies, R&D Advances And Clinical Data To Help You Fast-Track Next-Generation Therapeutics To Market

Antibody Engineering & Therapeutics ASIA is produced by **Informa Connect**, the same organizers as Antibody Engineering & Therapeutics US and Antibody Engineering & Therapeutics EUROPE. Bringing together renowned industry and academic scientists working in the areas of antibody and protein engineering and therapeutic development, this conference provides you with the latest information about antibody-related technologies and preclinical and clinical data on antibody, ADC, bispecific and immuno-oncology programs from around the world.

Register now to learn about cutting-edge scientific advances in the field and to find the partners you need to accelerate your next-generation antibodies towards commercial success.

Science

Accelerate Your Product to Market

Hear case studies, best practices and lessons learned from global antibody, protein, ADC and Immuno-oncology developers currently in preclinical and phase 1/2/3 clinical trials.

Technology

Evaluate New Technologies and Services

Improve your discovery, preclinical and clinical development by meeting with global technology leaders and service providers in the exhibit hall. The exhibit hall also features peer-submitted posters that contain new research from global scientists working in antibody and protein therapeutic development.

Networking

Meet Your Next Partner At Antibody Engineering & Therapeutics Asia

Connect with antibody, protein, ADC and immuno-oncology leaders across Asia, Europe and North America during networking lunches, poster sessions, dinners and cocktail receptions



Optional Pre-Conference Workshops
Monday, October 21, 2024

08:00 Morning Workshop Registration

Morning Pre-Conference Workshop: 8:30am- 12:30pm

Workshop A: Introduction to Antibody Engineering

Workshop Instructor:
David Bramhill, Ph.D., Founder, Bramhill Biological Consulting, LLC
and Research Corporation Technologies

Workshop Overview

Today's wealth of knowledge of antibody structures will be reviewed along with the genetics of diversity generation, to give insights into the best strategies for improving function. There is particular emphasis on the choice of a functional assay to effectively monitor the changes in a desired property, and the use of functional enrichment steps where a library approach is employed. Not only is amino acid sequence amenable to engineering, but glycan structures and other modifications may also be engineered. The course will focus on the engineering and enhancement of antibodies and antibody-like scaffolds. Examples will include work on antibody fragment affinity improvement by 100-fold to low pM affinity. Also, the engineering of bispecific antibodies by diverse approaches and the adaptation to generate Chimeric Antibody Receptor (CAR) constructs will be discussed. Expression platforms for producing antibodies for testing and for manufacture will also be covered. A background in biochemistry and molecular biology is useful, as the course is designed to progress rapidly from simple to advanced concepts.

Course Agenda

- Functions amenable to engineering: affinity, specificity, stability, solubility, immunogenicity
- The measure of success: functional assays
- Engineering by design
- Engineering by random mutation
- Designed libraries
- Display technologies
- Improving manufacturing by protein engineering methods
- Glycosylation engineering – function and homogeneity
- Other protein modifications
- Immunogenicity engineering
- Bispecific antibodies
- CAR-T strategies
- Expression of antibodies and fragments for discovery and testing
- Manufacturing platforms for antibodies and fragments

Add-on this optional pre-conference workshop to your main conference registration package and gain a comprehensive overview of antibody engineering in an easy-to-follow classroom setting to help you prepare for the main conference program. A short morning break will take place at 10:30.

NOTE: The afternoon workshop "Introduction to ADC Design and Development" is an excellent complement to this introduction course, and is recommended especially for chemists and biochemists who are new to the ADC field.

Optional Pre-Conference Workshops
Monday, October 21, 2024

12:30pm–13:00pm Networking Luncheon (for Full-Day Workshop Attendees Only)

13:00 Afternoon Workshop Registration

Afternoon Pre-Conference Workshop 13:30 – 17:30

Workshop B: Introduction to ADC Design and Development

Workshop Instructor:
David Bramhill, Ph.D., Founder, Bramhill Biological Consulting, LLC
and Research Corporation Technologies

Workshop Overview

This workshop covers the key aspects of ADC design, why each piece is important and how each can synergize to make an optimized product. It will give a comprehensive overview of the current state-of-the-art approaches available for ADCs and provides an introductory framework so participants can rapidly identify issues and solutions in their specific projects. It is aimed to provide even beginners with explanations of the nomenclature and science. The teams involved in ADC development need both chemists and biologists to work together effectively. The course provides an opportunity to better understand both aspects of the science and thus enhance communication within your team.

Workshop Topics To Be Discussed

- Antibody Structure
- Basic components of ADCs
- Payload decisions: Class of payload, Drug vs Pro-drug formats.
- Linker designs for release or stability
- Solubility issues for ADCs
- Bioconjugation by chemistry and enzyme
- Linkers and solubility

What Will You Learn?

- Gain an overview of the key aspects and design parameters for ADCs.
- Scientific terms and acronyms relating to ADCs will be defined and explained.
- Current state-of-the-art solutions for the various challenges faced in developing an ADC or bioconjugate.
- Better understand what the others in your ADC team are working to accomplish.

Who Should Attend?

Scientists and managers involved in the development of therapeutic bioconjugates – ADCs, nanoparticles, conjugate vaccines – in pharma and biotech companies. Note that the morning class “Introduction to Antibody Engineering” is an excellent complement to this course, and is recommended especially for chemists and other new to working with antibodies.

Add-on this optional pre-conference workshop to your main conference registration package and gain a comprehensive overview of ADC design and development in an easy-to-follow classroom setting to help you prepare for the main conference program. A short afternoon break will take place at 3:30.

Main Conference
Tuesday, October 22, 2024

08:00 ***Registration and Coffee***

08:25 **Chairperson's Remarks**
Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica, USA

Keynote Prensentation

08:30 **Design of Therapeutic Antibody with Engineered Binding Specificity**

While many of therapeutic monoclonal antibody rely on their highly specific and high affinity binding to their targets, we have previously reported that Fab of antibodies can be engineered to have pH dependent, calcium ion dependent or ATP dependent antigen binding. We now report novel antibodies in which the same paratope of Fab can be engineered to bind to multiple antigens having very low homology. These antibodies are now being tested in phase 1 clinical study.
Tomoyuki Igawa, Ph.D., Associate President, Head of Translational Research Division, Chugai Pharmaceutical Co., Ltd., Japan

Antibody Engineering, Discovery and Selection

09:00 **Selecting High-Afinity ph Selective Antibodies de Novo**

The Specifica Generation3 Library Platform is based on highly developable clinical scaffolds, into which natural CDRs purged of sequence liabilities have been embedded. The platform directly yields highly diverse, subnanomolar, developable, drug-like antibodies more potent than those from immune sources. This talk will discuss the extension of the platform to the direct selection of pH sensitive antibodies: binding better at pH 6.0, or binding better at pH 7.4.
Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica, USA

09:30 **Next-Generation Antibody Engineering and Design**
Kouhei Tsumoto, Ph.D., Professor and Director, Department of Bioengineering, Department of Chemistry and Biotechnology, The University of Tokyo, Japan

10:00 ***Networking Refreshment Break with Exhibit and Poster Viewing***

10:45 **Opening the Barn Door to Antibody Discovery**

OmniAb

The antibody repertoire generated by an animal in response to immunization results from its recognition of the target antigen, its native genetic diversification and cellular selection mechanisms, and the sequences of its immunoglobulin genes. All of these parameters are profoundly influenced by the host animal species and its genetics. OmniAb® accesses the biodiversity of six species to generate high-quality custom repertoires of human antibodies to empower therapeutic antibody discovery for a wide variety of targets and workflows.
Bill Harriman, Ph.D., Senior Vice President, Antibody Discovery, OmniAb, USA

11:15 **Writing the Future of Biologics with an Integrated Offering of Immunization, Libraries, and Machine Learning**

TWIST BIOSCIENCE

Twist Biopharma Solutions (TBS), a division of Twist Bioscience, combines DNA synthesis with antibody engineering expertise to provide end-to-end antibody discovery solutions. The result is a make-test cycle engine that yields better antibodies against challenging targets utilizing immunization, libraries, and machine learning. TBS continues to expand its capabilities in partnership with others to further utilize their make-test cycle.
Aaron Sato, Ph.D., Chief Scientific Officer, Twist Bioscience, USA

11:45 **Understanding the Biosynthesis of Human IgM through a Combinatorial Expression of Mutant Subunits that Affect Product Assembly and Secretion**

To gain insights into IgM's assembly mechanics that underwrite their high-level secretion, we characterized the biosynthetic process of a natural human IgM using a HEK293 cell platform. By creating a series of mutant subunits that differentially disrupt secretion, folding, and specific inter-chain disulfide bond formation, we assessed their effects on various aspects of IgM biosynthesis. The mutations caused a spectrum of changes in steady-state subcellular subunit distribution, ER-associated inclusion body formation, intracellular subunit detergent solubility, covalent assembly, secreted IgM product quality, and secretion output. Through this combinatorial approach, we consolidated overlapping yet fragmented knowledge on IgM biosynthesis while unexpectedly revealing that the loss of certain inter-chain disulfide bonds was tolerated in polymeric IgM assembly and secretion. The findings demonstrate the crucial role of underlying non-covalent protein-protein interactions in orchestrating the initial subunit interactions and maintaining the polymeric IgM product integrity during ER quality control steps, secretory pathway trafficking, and secretion.
Haruki Hasegawa, Ph.D., Scientific Director, Amgen

12:15 ***Late Breaking Presentation***

12:45 ***Networking Luncheon with Exhibit and Poster Viewing***

13:55 **Co-Chairs' Remarks**

Sai Reddy, Ph.D., Associate Professor of Systems and Synthetic Immunology, ETH Zurich, Switzerland
Cédric R. Weber, Ph.D., Director of Data Science and Bioinformatics, Alloy Therapeutics, Inc., Switzerland

AI-Enabled and Computationally-Guided Antibody Discovery & Engineering

14:00 **Machine Learning-guided Protein Engineering of Immune Receptors**

Determining the specificity of adaptive immune receptors— antibodies, and T cell receptors (TCRs) — is critical for understanding immune responses and advancing immunotherapy and drug discovery. Immune receptors exhibit extensive diversity in their variable domains enabling them to interact with a plethora of antigens. Despite the significant progress made by AI tools such as AlphaFold2 and AlphaFold3 in predicting protein structures, challenges remain in accurately modeling the structure and specificity of immune receptors, primarily due to the limited availability of high-quality crystal structures and the complexity of immune receptor-antigen interactions. Here, I will present advancements in sequence-based approaches for training machine learning models that predict immune receptor specificity.

Sai Reddy, Ph.D., Associate Professor of Systems and Synthetic Immunology, ETH Zurich, Switzerland

14:30 **Integration of AI and Wet-Lab Discovery for the Generation of Diverse Antibodies**

Satoshi Tamaki, Ph.D., CEO and CSO, MOLCURE Inc., Japan

15:00 **Optimizing Collaborations with AI Teams: A Primer for Scientists Exploring AI for Antibody Design**

EVQLV

Explore the essentials of collaborations between scientists and AI teams to understand the opportunities, challenges, and risks involved in AI-driven antibody design and how to best leverage data science and data scientists. Key topics include: project fit and feasibility using AI; real-world use cases of failure and success; optimal data to support AI-driven antibody design; communication challenges and opportunities between technologists and scientists; and data protection and intellectual property. Leave the presentation with a better understanding of how to leverage AI teams for your next antibody discovery and engineering campaign.

Brett Averso MS, Chief Technology Officer, EVQLV, USA

15:30 **Automated Bioinformatics Pipelines for Rapid In Silico Analysis – A Case Study of Versatile Antibody Assessment and In Vitro Selection**

PipeBio

The swift identification of promising antibody candidates from various generation methods is crucial for driving therapeutic development. This presentation examines the practical role of in silico analysis in expediting this process. Utilizing adaptable and user-friendly bioinformatics tools, we demonstrate how streamlined pipelines improve efficiency, aid in result interpretation, and facilitate the selection of optimal candidates across experiments. In this talk we present how Chiome Bioscience effectively uses the PipeBio bioinformatics platform to support and accelerate antibody discovery pipelines at the company.

Jannick Bendtsen, Ph.D., CEO, PipeBio, Denmark
Takahiro Matsusaka, Ph.D., Senior Scientist, Chiome Bioscience, Japan

16:00 ***Networking Refreshment Break with Exhibit and Poster Viewing***

16:30 **AbDiffuser: Full-atom Generation of In-vitro Functioning Antibodies**

We introduce AbDiffuser, an equivariant and physics-informed diffusion model for the joint generation of antibody 3D structures and sequences. AbDiffuser is built on top of a new representation of protein structure, relies on a novel architecture for aligned proteins, and utilizes strong diffusion priors to improve the denoising process. Our approach improves protein diffusion by taking advantage of domain knowledge and physics-based constraints; handles sequence-length changes; and reduces memory complexity by an order of magnitude, enabling backbone and side chain generation. We validate AbDiffuser in silico and in vitro. Numerical experiments showcase the ability of AbDiffuser to generate antibodies that closely track the sequence and structural properties of a reference set. Laboratory experiments confirm that all 16 HER2 antibodies discovered were expressed at high levels and that 57.1% of the selected designs were tight binders.

Andreas Loukas, Ph.D., Senior Principal Scientist and Machine Learning Lead, Roche, Switzerland

17:00 **De novo Structure-Based Antibody Design**

Despite the central role that antibodies play in modern medicine, there is currently no way to rationally design novel antibodies to bind a specific epitope on a target. I will discuss the development of a deep-learning pipeline capable of designing de novo antibodies that bind to user-specified epitopes. This pipeline designs diverse antibodies against several types of epitopes, the designs are readily affinity-optimized and we demonstrate that, for one design, the pipeline achieves atomic-level accuracy versus a cryo-EM structure.
Nate Bennett, Ph.D., Scientist, Xaira Therapeutics, USA

17:30 **Pioneering Data-Driven Strategies in De Novo Nanobody Design**

AI's potential to create antibodies from scratch is promising but hampered by poor hit rates and binding strengths, rooted in insufficient training data. We have addressed this issue by using computational simulations to determine data requirements such as modality, amount, and diversity. Simulations have been guiding our ongoing experimental data generation work, marking a shift towards a data-centric strategy that complements recent algorithmic progress, aiming to overcome current challenges.
Roberto Spreafico, Ph.D., Senior Director, Discovery Data Science, Genmab, The Netherlands

18:00–19:00 ***Networking Cocktail Reception with Exhibit and Poster Viewing***

Close Of Day

Main Conference
Wednesday, October 23, 2024

07:30 ***Registration and Coffee***

08:00 ***Chairperson's Remarks***

08:05 **Faster Time to Market through Digital Innovation in Biologics Research and Development**

Genedata

Biologics research and development present unique challenges in data management and analytics. Complex logistics, massive data streams from unique HT processes, and diverse modalities such as antibodies and bispecifics and cell and gene therapies require on-going advancement of fit-for-purpose digital technology and automation approaches. Digital innovation can significantly accelerate biologics R&D and it is increasingly seen as a competitive differentiator. We present use cases showing how biopharma and biotech organizations digitalize and automate their biologics workflows today and how they leverage having full traceability and data integrity for data sciences and machine learning.

Mizue Hisano, Ph.D., Scientific Business Consultant, Genedata Biologics, Genedata, Switzerland

Antibody-drug Conjugates (ADCs)

08:35 **Development of the DXd ADC Technology Platform and the Latest Clinical Results**

We have developed the novel ADC technologies, DXd ADC, using a highly potent topoisomerase I inhibitor as a payload and currently possess several assets, including ENHERTU, in clinical trials. In this presentation, I will introduce the DXd ADC technologies and share the latest clinical trial results.

Yasuyuki Kaneta, Ph.D., Senior Director, Daiichi Sankyo, Japan

09:05 **Delivery of a BET Protein Degrader via a CEACAM6-targeted Antibody-drug Conjugate Demonstrates Promising Anti-tumor Activity in Pancreatic Cancer Models**

Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of all cancers. PDAC organoid screening identified a novel payload of antibody–drug conjugate (ADC), a bromodomain and extra-terminal (BET) protein degrader named EBET. We selected CEACAM6 as an ADC target. The Anti CEACAM6-EBET induces marked tumor regression in various PDAC-patient-derived xenografts, with a decrease in the inflammatory phenotype of stromal cells. Combination with PD-1 antibody induces more sustained tumor regression.

Shuntaro Tsukamoto, Ph.D., Research Scientist, Tsukuba Research Laboratories, Eisai Co., Ltd., Japan

09:35 **A Novel Dual-payload ADC Platform to Overcome Payload Resistance and Maximize Therapeutic Promise**

Payload resistance is a critical concern for ADCs: patients progress, narrow payload diversity, and limited validation of novel modes-of-action. Combining ADCs with other drugs may be beneficial but therapeutic windows are limited. Hummingbird Bioscience's dual-payload ADC platform presents a targeted, single-agent approach designed to overcome resistance and maximize therapeutic window.

Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer and Co-Founder, Hummingbird Bioscience

10:05 ***Networking Refreshment Break with Exhibit and Poster Viewing***

Antibody Therapeutics in the Clinic: Lessons Learned

10:45 **Innovative Avenues Exploration in Treatment Development for Alzheimer's Disease**

Pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis of all cancers. PDAC organoid screening identified a novel payload Eisai has been tackling development of therapies for Alzheimer's disease (AD) for over 4 decades. Eisai had spent a long time with a lot of development failures of disease modifying therapies for AD, but we had never given up and then eventually developed anti-Ab protofibril antibody, Lecanemab, in 2023.

Satoshi Ito, Associate Director, Project Management Office of Global AD Office, Eisai Co., Ltd., Japan

11:15 **Development Overview of Bispecific DuoBody®-PD-L1×4-1BB (Acasunlimab): Next Generation Cancer Immunotherapy**

Acasunlimab, a novel bi-specific antibody generated with DuoBody platform, targeting PD-L1 and 4-1BB, enhances T cell anti-tumor activity by blocking PD-L1 and inducing conditional activation of 4-1BB signaling. In preclinical studies, it effectively binds to its targets, enhances activation and proliferation of TCR-stimulated T cells and induces tumor regression without causing systemic toxicity. In a phase I/IIa study, Acasunlimab showed promising safety and efficacy profiles across various tumor types and further study is currently ongoing. We will present an overview of Acasunlimab development with key pre-clinical and clinical data.

Ben Hatano, M.D., Ph.D., Head of Clinical Science, Genmab, Jaoshi Ito, Associate Director, Project Management Office of Global AD Office, Eisai Co., Ltd., Japan

Imaging Approaches and Antibody Theranostics

11:45 **Development of NMT25/NMK89 As Theranostics Agents with Novel Platform Technology: 225Ac/89Zr-abeled Antibody Targeting MUC5AC for Pancreatic Cancer**

We have been conducting research on radio-theranostics with our proprietary platform technology. The most advanced pipeline, NMT25, is an Ac-225 labeled humanized antibody against MUC5AC, which is highly expressed in pancreatic cancer. NMT25 has demonstrated good pharmacokinetics and excellent antitumor efficacy in animal models. A Phase I study of the diagnostic agent NMK89, a theranostic pair of NMT25, is currently under way. In this presentation, we introduce our efforts in radio-theranostics development, focusing on NMT25/NMK89.

Yoshifumi Maya, Ph.D., Group Manager, Nihon Medi-Physics, Japan

12:15 **On-demand Molecular Imaging: For Design Feedback, Direct Epitope Mapping, and Status Monitoring**

Quick feedback on what people designed and produced and how they exist in their hands is essential for developing novel molecules and formats, but it isn't easy to happen. Rigaku developed a 'solution molecular microscope' that can image the molecular complexes in a solution that enables direct epitope mapping, molecular defects and aging, and nucleotide/protein quantitation of vector complexes.

Takashi Sato, Ph.D., Senior Scientist, Life Science Product Division, Rigaku Corporation, Japan

12:45 ***Networking Luncheon with Exhibit and Poster Viewing***

13:55 **Chairperson's Remarks**

Shohei Koide, Ph.D., Professor of Biologics Design, Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, USA

Bispecific and Multispecific Antibodies

14:00 **Multispecific Antibodies Application for Inflammation and Oncology - Design and Clinical Outcomes**

Multispecific antibodies are widely used in Immunooncology. We expand their use also to Inflammation with learning from the past and translating knowledge of multispecific antibody design from oncology to inflammation. Important design principles are shared and the advantages of Numab's platform presented. The audience will be updated with pre-clinical and clinical data.

Stefan Warmuth, Ph.D., SVP, Head Technology and CMC, Numab Therapeutics AG, Switzerland

14:30 **Rapid and Efficient Generation of Format-diverse Multispecific Antibody Panels via Complementary Technologies**

There is increasing understanding that currently approved monospecific checkpoint inhibitors are not sufficiently effective for all patients and/or indications. Thus, investigators are interested in targeting multiple signaling pathways and/or cell types to enhance the depth and breadth of clinical outcomes, often in the form of multispecific antibody treatments ('multispecifics'). The large number of possible topologies and complexity of manufacturing of multispecifics necessitates the development and application of a robust set of complementary technologies. We have developed an exemplary set of such technologies, and herein, demonstrate the ability to direct desired antibody chain pairing (HC-HC and HC-LC), isolate and engineer single-domain antibodies, as well as generate large panels of multispecific antibodies with diverse topologies from a limited number of input molecules. Specifically, we demonstrate these capabilities in the context of T cell engaging (TCE) multispecifics that leverage our affinity- and developability-optimized aCD3 and aCD28 antibody panels.

Robert Pejchal, Ph.D., Vice President, Antibody Engineering, Adimab, USA

15:00 **Unleashing Therapeutic Potential: Bispecific Antibodies Targeting Herpes Simplex Virus Infection for Chronic Suppressive Therap**

Recurrent genital herpes are mostly caused by Herpes simplex virus-2 and no effective treatment is currently available. We engineered dual-action neutralizing antibodies blocking viral entry and cell-to-cell spread. Promising results in reducing viral shedding and lesions in vivo suggest a transformative approach for chronic suppressive therapy.

Vivian Lee, Senior Research Scientist, Protein Therapeutics, Gilead Sciences, USA

15:30 **Novel Bispecific Antibody Format with Reliable Productivity and Developability and Its Product Application**

Bispecific antibodies are a rapidly growing and clinically validated class of antibodies with marketed drugs. We have designed a novel tetravalent symmetrical bispecific antibody format called REGULGENTTM, which utilizes four Fab domains with a common light chain. REGULGENTTM demonstrates an ideal profile for commercial use by avoiding the formation of unintended molecules, resulting in high expression levels. We further show the product applications using this format.

Makoto Nakayama, Director, Kyowa Kirin, Japan

16:00 ***Networking Refreshment Break with Exhibit and Poster Viewing***

Alternative Non-Antibody Scaffolds

16:30 **Targeting Intracellular Cancer Drivers with Monobodies**

Many cancers are driven by hyperactive mutants of intracellular proteins, most of which remain undruggable by the conventional approach with small molecule drugs. I will discuss biologics-based strategies to effectively target intracellular cancer drivers, including facile development of monobodies that are exquisitely selective to oncogenic mutants over their wild-type counterparts, and intracellular delivery of such monobodies.

Shohei Koide, Ph.D., Professor of Biologics Design, Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, USA

17:00 **Antibody-like Proteins Targeting Proteins and Small Molecules**

In this presentation, I will describe the development of a D-monobody against MCP-1 using mirror image display. The obtained D-monobody showed efficient inhibition of MCP-1 activity (IC50 = 2 nM). I will also present a monobody and anticalins targeting small molecule ligands for bio-analytical applications.

Hiroshi Murakami, Ph.D., Professor, Department of Biomolecular Engineering, Nagoya University, Japan

17:30 **New Methodology for Discovering An Orally Bioavailable Peptide and Its Application for Developing a RAS Inhibitor**

Establishment of a technological platform for the creation of cell-permeable peptides enabling targeting of intracellular proteins could be a major step toward developing innovative drugs. We have discovered the drug-likeness criteria for cyclic peptides and established a new peptide drug discovery platform by developing library technologies affording highly N-alkylated cyclic peptide hits. As an example of its utilization, the discovery of a RAS inhibitory clinical compound (LUNA18) will be reported.

Hiroko Yamashita, Senior Scientist, Mid-Size Molecule Unit, Chugai Pharmabody Research, Singapore

18:00 ***Close Of Conference***

Limited Space Available: Reserve Your Exhibit Booth and Sponsorship Today

Become a sponsor or exhibitor and connect face-to-face with 350+ highly influential scientists, engineers and executives from industry and academia with the budget and authority to recommend, specify and approve the purchase of products and services to accelerate antibody research, discovery efforts and clinical programs.

Showcase your products and services directly to this audience of antibody researchers and senior decision makers through: A wide variety of options are available to help you meet your company objectives before, during and after the conference.

• Exhibition Packages • Thought Leadership Presentations • High Visibility Onsite Branding • Custom Onsite Video Interviews

Sponsors

EVOLV OmniAb PipeBio

Rigaku TWIST BIOSCIENCE Genedata

Exhibitors

BIOINTRON IQVIA LABORATORIES

Media Partners

The Antibody Society JAPAN ASK The Antibody Society Korea JBA Japan Bioindustry Association